Status: Recruiting
A Prospective Longitudinal Analysis of Faricimab (Vabysmo 6mg) For Choroidal Neovascularization in Presumed Ocular Histoplasmosis Syndrome
This study will evaluate the safety and effects, good or bad of faricimab (Vabysmo®), a drug that is approved by the U.S. Food and Drug Administration (FDA) for other retinal conditions, but its use is considered investigational when used specifically for choroidal neovascularization (CNV) related to presumed ocular histoplasmosis (POHS)
Participants needed: 25
Trial details
Phase: Phase 4Age: 18+Biological sex: AllType: InterventionalSponsor: Cincinnati Eye Institute, Southwest OhioUpdated: Jul 10, 2026Locations: 2
Eligibility criteria
Age ≥18 years at the time of signing the Informed Consent Form [+9]
Known hypersensitivity to faricimab or any of its excipients Faricimab [+33]